PharmGen Science Inc Cash Flow-to-Debt Ratio
PharmGen Science Inc cash flow-to-debt ratio. PharmGen Science Inc (004720) has a Cash Flow-to-Debt Ratio of 0.02x as of September 2025, meaning its operating cash flow of ₩1.91 Billion could theoretically repay 0% of its total liabilities (₩83.70 Billion) in one year. Check cash flow reinvestment rate of PharmGen Science Inc to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of PharmGen Science Inc (2011–2024)
Cash flow-to-debt ratio of PharmGen Science Inc from 2011 to 2024. Historical debt coverage capacity for PharmGen Science Inc across 13 annual periods. Check PharmGen Science Inc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
PharmGen Science Inc Cash Flow-to-Debt Ratio by Year (2011–2024)
PharmGen Science Inc cash flow-to-debt ratio by year from 2011 to 2024. Year-by-year debt coverage analysis for PharmGen Science Inc. For the full cash flow conversion analysis, see cash efficiency ratio of PharmGen Science Inc.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.02x | ₩2.38 Billion | ₩114.02 Billion | ▼ -58.6% |
| 2023 | 0.05x | ₩5.44 Billion | ₩107.71 Billion | ▲ +533.0% |
| 2022 | -0.01x | ₩-1.29 Billion | ₩110.28 Billion | ▼ -114.0% |
| 2021 | 0.08x | ₩7.78 Billion | ₩93.39 Billion | ▲ +61.9% |
| 2020 | 0.05x | ₩2.68 Billion | ₩51.97 Billion | ▼ -10.7% |
| 2019 | 0.06x | ₩2.52 Billion | ₩43.79 Billion | ▼ -43.5% |
| 2018 | 0.10x | ₩4.22 Billion | ₩41.35 Billion | ▼ -3.3% |
| 2017 | 0.11x | ₩1.84 Billion | ₩17.43 Billion | ▼ -62.1% |
| 2016 | 0.28x | ₩7.75 Billion | ₩27.89 Billion | ▲ +36.6% |
| 2015 | 0.20x | ₩3.62 Billion | ₩17.79 Billion | ▲ +321.3% |
| 2014 | -0.09x | ₩-2.02 Billion | ₩21.93 Billion | ▲ +66.1% |
| 2013 | -0.27x | ₩-4.20 Billion | ₩15.49 Billion | ▼ -326.3% |
| 2011 | 0.12x | ₩2.89 Billion | ₩24.13 Billion | — |